AB Science Secures €25M Insurance for ALS Trial Amid Strategic Reorganization

Event summary

  • AB Science secured a €25M Clinical Trial Funding Insurance policy from MCI for its Phase III ALS trial, covering costs in case of failure.
  • The policy, arranged by Acrisure Re, has no deductible and is effective upon first patient enrollment, with a binding offer valid until December 31, 2026.
  • AB Science temporarily halted clinical trial recruitment in Europe due to concerns from health authorities about its resources and structure.
  • The company is deprioritizing mastocytosis and mast cell activation programs, focusing instead on ALS and AML trials.
  • The Phase III ALS trial (AB23005) will enroll 408 patients and compare masitinib plus riluzole against placebo plus riluzole.

The big picture

AB Science's €25M insurance deal for its ALS trial signals institutional confidence in the program, even as the company faces regulatory scrutiny over its operational structure. The strategic reorganization—deprioritizing lower-potential programs and focusing on ALS and AML—reflects a broader industry trend of biopharmaceutical firms streamlining pipelines to manage risk and improve capital efficiency. The insurance structure, which protects against trial failures, could enhance AB Science's ability to attract debt and equity financing, though the temporary halt in Europe introduces execution risks.

What we're watching

Insurance Activation
Whether AB Science will activate the binding insurance offer before the December 31, 2026 deadline and how it will impact the company's financial flexibility.
Regulatory Compliance
The pace at which AB Science strengthens its organization to address European health authorities' concerns and resume clinical trials.
Trial Execution
How the temporary halt in Europe affects the timeline and success of the Phase III ALS trial, given the policy's coverage of recruitment failures.

Related topics

Oncology